MR MRNA Moderna Inc. 로딩 중... : 애널리스트의 강세 및 약세 의견

Vertex discontinued its VX522 mRNA therapy for CF due to tolerability issues (lung inflammation from the LNP delivery), establishing that LNP-based inhaled delivery remains an unsolved problem for the last ~5,000 CF patients who produce no CFTR protein. — This indicates a persistent limitation of current LNP delivery technology, which could affect the pipeline strategies of other companies working on inhaled mRNA therapies.